Loading clinical trials...
Loading clinical trials...
A Phase 1 Pharmacokinetic Comparability Study in Healthy Subjects to Evaluate the Relative Bioavailability of Risankizumab in Vials Manufactured by Two Different Processes
Conditions
Interventions
Risankizumab
Locations
3
United States
Anaheim Clinical Trials LLC /ID# 260740
Anaheim, California, United States
Clinical Pharmacology of Miami /ID# 260800
Miami, Florida, United States
Acpru /Id# 260864
Grayslake, Illinois, United States
Start Date
November 20, 2023
Primary Completion Date
May 6, 2024
Completion Date
May 6, 2024
Last Updated
May 14, 2024
NCT00104325
NCT07118891
NCT01399385
NCT03807401
NCT07499050
NCT05196061
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions